Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.16.2 (
PCP
)
3,761
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A reactive ATP analog, N6-(6-bromoacetamidohexyl)-AMP.
PCP
, was synthesized in an attempt to covalently label the binding sites for adenine nucleotides, especially ATP, of various enzymes which utilize adenine nucleotides as substrates, cofactors, inhibitors or allosteric effectors. This reagent rapidly inactivated rabbit muscle glyceraldehyde 3-phosphate dehydrogenase (GPD), myokinase (MK), and
creatine kinase
(CK) under very mild conditions. Adenine nucleotide substrates prevented the inactivation. In the case of GPD, complete inactivation was observed when 1 mol of the reagent per mol of enzyme subunit was incorporated into the enzyme. These results indicate that the present ATP analog may be useful as an affinity labeling reagent for various adenine nucleotide-dependent enzymes.
...
PMID:Synthesis of a reactive ATP analog and its preliminary application as an affinity labeling reagent. 56 99
The effect of the ADP receptor antagonists ATP and adenosine 5'-(beta, gamma-methylene)triphosphate (AMP-
PCP
), and the ADP-utilizing enzyme systems
creatine phosphokinase
/creatine phosphate (CPK/CP) and pyruvate kinase/phosphoenol pyruvate (PK/PEP) on platelet deposition onto type I collagen was examined. An in vitro perfusion system was used, which allowed continuous visualization of the deposition of fluorescently labelled platelets. This system also provide well-controlled rheology, precise quantification of deposition, and allowed the use of heparinized whole human blood (3 u/ml). Heparinization at this level permits the local generation of thrombin near surface platelet aggregates. The contribution of ADP is thus studied with the combined effects of thrombin, thromboxane A2, and other aggregating agents present. Results from these studies indicate that ATP was capable of inhibiting deposition by 60% at 1 microM and 90% at 5 microM (whole blood conc.). AMP-
PCP
inhibited deposition in a dose dependent manner with a Ki of approximately 80 microM and a maximum inhibition of 60%. Inhibition by CPK/CP was measured at 20, 40, and 60 u/ml, with approximately 45% inhibition achieved for the latter two concentrations. PK/PEP at 60 u/ml resulted in 70% inhibition. These results support a role for ADP in mediating platelet recruitment in thrombus growth on collagen. Previous work utilizing animal bleeding times supports this conclusion; the present study demonstrates that this role is not dependent upon endothelial or vasoconstrictive effects. Intraplatelet cAMP levels were raised with respect to controls upon exposure to ATP at 8.3 microM (p less than 0.025), and 15 microM (p less than 0.005), as well as AMP-
PCP
at 42-500 microM (p less than 0.005).(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:ADP receptor antagonists and converting enzyme systems reduce platelet deposition onto collagen. 132 10
Acute cerebral ischemia and reperfusion injury of rabbits was produced by permanently occluding the vertebral arteries and temporarily clamping the common carotid arteries for 30 min. Phencyclidine [1-(phenylcyclohexyl)piperidine,
PCP
] 40-80 micrograms.kg-1 icv 30 min before ischemia significantly attenuated the decrease of the total power of electroencephalogram (EEG) within 30 min of ischemia and improved the recovery of brain electric activity following reperfusion.
PCP
20-80 micrograms.kg-1 dose-dependently suppressed the
creatine kinase
(CK) release during cerebral ischemia and reperfusion, and
PCP
40-80 micrograms.kg-1 reduced brain ischemic damage. These improvements indicated that
PCP
has protective effects on acute cerebral ischemia and reperfusion injury.
...
PMID:Neuroprotective effects of phencyclidine on acute cerebral ischemia and reperfusion injury of rabbits. 144 2
Twenty-three blood constituents were analyzed in rats chronically injected with phencyclidine (
PCP
, angel dust). After receiving three injections weekly for an average of 9 months the only analyte to significantly change was
creatine phosphokinase
(
CPK
), which showed a threefold elevation over the saline injected controls.
...
PMID:Effect of chronic phencyclidine administration upon blood biochemical profiles in rats. 668 96
The myopathy induced in the rat by the central nervous system stimulant, phencyclidine (
PCP
), and restraint is characterized by extensive myofibrillar sarcomere disruption in hind limb muscles and massive increases in plasma
creatine kinase
(CPK) activity. The effects of dantrolene sodium on this myopathy were studied to determine if modulation of calcium release from the sarcoplasmic reticulum could alter the development of the myopathy. Dantrolene prevented both the sarcomere disruption and the increase in plasma CPK activity produced in the
PCP
-restraint model. The inhibitory effect was not due to a decrease in the locomotor activity produced by
PCP
. The findings are consistent with a role for excess sarcoplasmic calcium, originating from the sarcoplasmic reticulum, in the development of this myopathy.
...
PMID:Retention of sarcoplasmic calcium inhibits development of the phencyclidine-restraint experimental myopathy. 682 47